[Effectiveness of biomarker determination (TIMP 2*IGFBP 7) early detection of acute kidney injury in acute patients]
Rodríguez-Rojas L, García-Carpintero EE
Record ID 32018016169
Spanish
Original Title:
Efectividad de la determinación de biomarcadores (TIMP 2*IGFBP 7) para la detección precoz de insuficiencia renal aguda en pacientes agudos
Authors' objectives:
To evaluate the diagnostic effectiveness and clinical utility of urinary TIMP-2*IGFBP-7 measurement for the early detection of AKI in acutely ill patients, and to assess its economic, ethical, legal, organizational, and social implications.
Authors' results and conclusions:
Twenty-five prospective cohort studies evaluating the diagnostic performance of the biomarker were identified. The meta-analysis showed a pooled sensitivity of 64% and specificity of 71%, with a diagnostic odds ratio of 4.39, indicating limited diagnostic performance. Considerable heterogeneity was observed across studies. In patients with more severe AKI (KDIGO stages 2–3), sensitivity increased to 71% and specificity was 65%. Among ICU patients, sensitivity and specificity were 81% and 51%, whereas in cardiovascular surgery patients they were 54% and 73%, respectively.
Evidence regarding clinical utility was limited. Only one of three randomized clinical trials evaluating biomarker-guided treatment strategies, conducted in patients after cardiovascular surgery, demonstrated a reduction in AKI incidence through the implementation of nephroprotective measures. The other two trials were stopped early because of futility.
Economic evaluations suggested that NEPHROCHECK® may be cost-effective in specific patient populations, particularly those admitted to the ICU, and may save healthcare costs.
Conclusions: Overall, the available evidence indicates that the test has moderate diagnostic accuracy and a potentially limited clinical benefit, mainly in patients undergoing cardiovascular surgery.
Authors' methods:
A systematic review of the scientific literature was conducted, including systematic reviews and original studies. Methodological quality and certainty of evidence were assessed using validated tools.
Details
Project Status:
Completed
Year Published:
2026
URL for published report:
https://hdl.handle.net/20.500.12105/27797
URL for additional information:
https://redets.sanidad.gob.es/productos/buscarProductos.do?metodo=detalle&id=1518
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Acute Kidney Injury
- Biomarkers
- Critical Care
- Rapid Diagnostic Tests
- Kidney Function Tests
Keywords
- acute kidney injury
- biomarkers
- TIMP-2*IGFBP-7
Contact
Organisation Name:
Agencia de Evaluacion de Tecnologias Sanitarias
Contact Address:
Instituto de Salud "Carlos III", Calle Sinesio Delgado 6, Pabellon 4, 28029 Madrid, Spain. Tel: +34 9 1 822 2005; Fax: +34 9 1 387 7841;
Contact Name:
Esther E. García Carpintero
Contact Email:
eegarcia@isciii.es
Copyright:
Agencia de Evaluacion de Tecnologias Sanitarias
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.